Publications by authors named "Richard Penson"

Claim this Profile
L
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.
Panagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, Tien V Le, Susana Campos

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers.
Mengyao Xu, Syem K Barakzai, Raj Kumar, Irva Veillard, Eugene Kim, Richard Penson

Signal Transduct Target Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Results of a Phase 2 Study of Adjuvant Proton Radiation Therapy for Node-Positive Cancer of the Uterus and Cervix.
Andrea L Russo, Nicolas Depauw, Nora K Horick, Jennifer Y Wo, Jacqueline A Nyamwanda, Richard T Penson

Int J Radiat Oncol Biol Phys· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
Elizabeth K Lee, Niya Xiong, Carolyn Krasner, Madeline Polak, Susana Campos, Richard T Penson

Gynecol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PRIMAry point: health-related quality of life (HRQoL).
Richard T Penson

Ann Palliat Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
Giovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo, David Cibula, Charles A Leath, Richard T Penson

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.
Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, Carolyn Krasner, Susana M Campos, Richard T Penson

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
Katherine Elizabeth Francis, Sandy Simon, Val Gebski, Florence Joly, Jonathan A Ledermann, Richard T Penson

Gynecol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Joyce F Liu, Niya Xiong, Robert M Wenham, Andrea Wahner-Hendrickson, Deborah K Armstrong, Richard T Penson

Gynecol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
Ryan B Corcoran, Khanh T Do, Jeong E Kim, James M Cleary, Aparna R Parikh, Richard T Penson

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, Alexandre André B A da Costa, Doga Gulhan, Richard T Penson

JCO Precis Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer.
Nicholas Hirschl, Wildnese Leveque, Julia Granitto, Valia Sammarco, Mervyns Fontillas, Richard T Penson

Cancers (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer, Ashley F Haggerty, Edwin A Alvarez, Richard T Penson

J Clin Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Yvette Drew, Jae-Weon Kim, Richard T Penson, David M O'Malley, Christine Parkinson

Clin Cancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Sandro Pignata, Michael Bookman, Jalid Sehouli, Austin Miller, Richard T Penson

Gynecol Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Krishnansu S Tewari, Michael W Sill, Michael J Birrer, Richard T Penson, Helen Huang

Gynecol Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
Richard T Penson, Allison J Ambrosio, Christin A Whalen, Carolyn N Krasner, Panagiotis A Konstantinopoulos

Oncologist· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Panagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, Carolyn Krasner, Susana Campos, Richard T Penson

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
Susana Campos, Ursula Matulonis, Suzanne Berlin, Neil Horowitz, Joyce Liu, Richard Penson

Int J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, Carolyn Krasner, Neil Horowitz, Richard T Penson

JAMA Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Fabian Trillsch, Sven Mahner, Beyhan Ataseven, Rebecca Asher, Nanda Aryal, Richard T Penson

Gynecol Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An update on the safety of olaparib for treating ovarian cancer.
Kelsi Cottrell, Caroline L Clark, Richard T Penson

Expert Opin Drug Saf· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies.
Susana M Campos, Suzanne Berlin, Carolyn N Krasner, Christin Whalen, Tina Atkinson, Richard T Penson

Cancer Chemother Pharmacol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.
Benoit You, Gilles Freyer, Antonio Gonzalez-Martin, Stephanie Lheureux, Iain McNeish, Richard T Penson

Cancer Treat Rev· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Carolyn N Krasner, Susana M Campos, Chantay L Young, Karan R Chadda, Hang Lee, Richard T Penson

Gynecol Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis